drugset / Trial / NCT05332340
Safety, Tolerability and Pharmacokinetics (PK) Evaluation of BZ371A, Topically Administered
Phase 1
Completed
12 enrolled
Biozeus Biopharmaceutical S.A.
Azidus Brasil Scientific Research and Development Ltda · collab
NaSingle-groupOpen-labelSupportive care
Summary
The purpose of this study is to evaluate pharmacokinetics, safety and tolerability profile of BZ371A topically administered in healthy patients.
Timeline
- Start
- 2022-11-16
- Primary completion
- 2022-11-30
- Completion
- 2022-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BZ371A | Unknown | 1.5 ml | Topical |
| Subject | BZ371A | Unknown | 5 mg/ml | Topical |